Page 15 - A9Rc19d2z_zddyc4_fc0.tmp
P. 15

NIHR studies due to report in 2020

                     EDNA:    Early Detection of Neovascular Age-related macular degeneration

                     EFREEZE:   A randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of
                              freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of
                              fresh embryo transfer in women undergoing in-vitro fertilization

                     MASTER:   Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress
                              incontinence after prostate surgery: Evaluation by Randomised trial






                  The long-running ‘TISU’ trial, comparing       different biomarker tests for assessing the risk of
                  extracorporeal shockwave lithotripsy versus    acute kidney injury in critically ill patients who are
                  ureteroscopic removal as a treatment for ureteric   considered for admission to critical care. The National
                  stones, reported to the funder in 2019. Publication   Institute for Health and Care Excellence (NICE) are
                  of the economic evaluation findings is expected   expected to publish guidance on this in 2020. AoT
                  in 2020. The year 2019 also saw publication of the   researchers have also contributed to four further
                  economic evaluation findings from three trials that   technology appraisals that commenced in 2019.
                  completed follow-up in recent years: the ‘CLASS’   Further, NICE has published Technology Appraisal
                  trial, comparing different treatment modalities   guidance on the use of three new technologies in NHS
                  for patients with varicose veins; the ‘GOT-IT’ trial,   England, for which researchers in the theme critiqued
                  assessing the effectiveness of glycerine triturate for   the economic evidence and company submitted
                  retained placenta; and the HEALTH trial, comparing   economic models.
                  sub-total hysterectomy to endometrial ablation for
                                                                 Broader Measures of Value
                  the treatment of heavy menstrual bleeding. Work
                  also continued on several NIHR funded trials that are   The theme’s ongoing interest in methods for
                  due to report to the funder in 2020. These include   incorporating broader measures of value in economic
                  the ‘EDNA’, ‘EFREEZE’, and ‘MASTER’ trials. Long-term   evaluation continued to evolve alongside our applied
                  follow-up of the previously reported ‘PROSPECT’ and   project work in 2019. One PhD project being carried
                  ‘VUE’ trials is also due in 2020.              out alongside our work in the area of endometriosis is
                                                                 exploring methods for measuring and incorporating
                  It has been a busy year with respect to the theme’s
                                                                 variation in patient preferences into an economic
                  ongoing involvement in the University of Aberdeen’s
                                                                 evaluation of alternative treatment approaches. This
                  Technology Assessment Reviews (TAR) contract
                                                                 will help determine whether economic evaluation
                  (see Projects In-Progress and Completed 2019).
                                                                 can be used to inform the delivery of more person-
                  Researchers from the theme were involved in a large
                                                                 centred approaches to care that are being advocated
                  review and economic modelling exercise to evaluate
                                                                 by health systems throughout the world.
                  the diagnostic accuracy and cost-effectiveness of



            HERU ANNUAL REPORT 2019                                                                             15
   10   11   12   13   14   15   16   17   18   19   20